Treatment of Chronic Viral Hepatitis Anno 1990

References

• Schalm S W, Summerskill W HJ, Gitnick G L, Elveback LR. Contrasting features of severe chronic active liver disease with and without hepatitis Bs antigen. Gut 1976; 17: 1422–1430
   Google Scholar
• Lam K C, Lai C L, Ng R P, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 1981; 304: 380–386
   PubMed Web of Science ®Google Scholar
• A trial group of the European Association for the Study of the Liver. Streroids in chronic B-hepatitis. A randomized, double-blind, multinational trial on the effect of low-dose, long-term treatment on survival. Liver 1986; 6: 227–232
   PubMedGoogle Scholar
• Greenberg H B, Pollard R B, Lutwick L I, Gregory P B, Robinson E S, Merigan TC. Effect of human leucocyte interferon on hepatitis B virus infection inpatients with chronic active hepatitis. N Engl J Med 1976; 295: 517–522
   PubMed Web of Science ®Google Scholar
• Weimar W, Heijtink R A, Ten Kate F JP, Schalm S W, Masurel N, Schellekens H. Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis. Lancet 1980; 1: 336–338
   PubMedGoogle Scholar
• Hoofnagle J H, Mullen K M, Jones D B, et al. Pilot study of recombinant human alpha-interferon in chronic nonAnonB hepatitis. N Engl J Med 1986; 315: 1575–1578
   PubMed Web of Science ®Google Scholar
• Rosina F, Saracco G, Actic G C, et al. Treatment of chronic delta hepatitis with alpha-2 recombinant interferon (IFN). Gastroenterology 1986; 90: 1762
   Google Scholar
• Review by an international group Acute and chronic hepatitis revisited. Lancet 1977; 2: 914–919
   PubMed Web of Science ®Google Scholar
• Hoofnagle J H, Shafritz D A, Popper H. Chronic type B hepatitis and the “healthy'” HBsAg carrier state. Hepatology 1987; 7: 758–763
   PubMed Web of Science ®Google Scholar
• Fattovich G, Brollo L, Alberti A, Pontisso P, Realdi G, Ruol A. Chronic persistent hepatitis type B: a clinical and morphological follow-up study. J Hepatology 1990, in press
   Google Scholar
• Realdi G, Alberti A, Rugge M, Bortolli F, Rigoli A M, Tremolada F. Seroconversion from hepatitis B e antigen to antiHBe in chronic hepatitis B virus infection. Gastroenterology 1980; 195: 195–199
   Google Scholar
• Schalm S W, Heijtink RA. Spontaneous disappearance of viral replication and liver cell inflammation in HBsAg-positive chronic active hepatitis: Hepatology 1982; 6: 791–794
   Google Scholar
• Shafritz DA. Hepatitis B virus DNA molecules in the liver of HBsAg carriers: mechanistic considerations in the pathogenesis of hepatocellular carcinoma. Hepatology 1982; 2(35)S–41S
   Google Scholar
• Yoshino I, IijimaTImai Y, Nambu M, Namiaisa. The natural history of the HBsAg chronic carrier state in Japanese National Railway. Hepatology 1983; 3: 1085
   Google Scholar
• Scotto J, Hadchouel M, Hery C, Yvart J, Tiollais P, Brechot C. Detection of hepatitis B virus DNA in serum by a simple spot hybridization technique: comparison with results for other viral markers. Hepatology 1983; 3: 279–284
   PubMed Web of Science ®Google Scholar
• Kuhns M C, McNamara A L, Cabal C M, . A new assay for the quantitative detection of hepatitis B viral DNA in human serum. Viral hepatitis and liver disease, AJ Zuckerman, et al. Alan R. Liss, New York 1988; 258–262
   Google Scholar
• Schalm SW, De Man RA, Thomas HC, Jacyna M, Hadziyannis SJ, Manessis E. Chronic hepatitis B: therapeutic controversies and randomized controlled trials. Gastroenterol Int 1989; 2: 16–24
   Google Scholar
• Carmen W F, Hadziyannis S, McGarvey M J, Jacyna M R, Karayiannis P, Makris A. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588–591
   PubMedGoogle Scholar
• Huang SN. Immunohistochemical demonstration of hepatitis B core and surface antigens in paraffin sections. Lab Invest 1975; 33: 88–95
   PubMed Web of Science ®Google Scholar
• Alexander G J, Brahm J, Fagan E A, et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987; 2: 66–68
   PubMed Web of Science ®Google Scholar
• Schalm S W, Heijtink R A, Van Buuren H R, de Man RA. Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B. Lancet 1985; 1: 358–360
   Google Scholar
• Garcia G, Smith C I, Weissberg J I, et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leucocyte interferon in the treatment of chronic hepatitis B. Ann Intern Med 1987; 107: 278–285
   PubMed Web of Science ®Google Scholar
• Perillo R P, Regenstein F G, Peters M G, et al. Prednisone withdrawal followed by recombinant alpha-interferon in the treatment of chronic type B hepatitis. A randomized controlled trial. Ann Intern Med 1988; 109: 95–100
   PubMedGoogle Scholar
• Kuo G, Choo Q L, Alter H J, et al. An assay for Circulating antibodies to a major etiologic virus of human nonAnonB hepatitis. Science 1989; 244: 362–364
   PubMed Web of Science ®Google Scholar
• McFarlane I G, Smith H M, Johnson P J, Bray G P, Vergani D, Williams R. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?. Lancet 1990; 754–757
   PubMedGoogle Scholar
• Davis G L, Balart L A, Schiff E R, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–1506
   PubMed Web of Science ®Google Scholar
• Thomson B J, Doran M, Lever A MI, Webster A DB. Alpha-interferon therapy for nonAnonB hepatitis transmitted by gammaglobulin replacement therapy. Lancet 1987; 1: 539–541
   PubMed Web of Science ®Google Scholar
• Jacyna M R, Brooks M G, Loke R HT, Main J, Murray-Lyon I M, Thomas HC. Randomised controlled trial of interferon alpha (lymphoblastoid interferon) in chronic nonAnonB hepatitis. Br Med J 1989; 80–82
   PubMedGoogle Scholar
• Di Bisceglie A M, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–1510
   PubMed Web of Science ®Google Scholar
• Hoofnagle J H, Di BIsceglie AM. Treatment of chronic type C hepatitis with alpha-interferon. Semin Liver Dis 1989; 9: 259–263
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Verme G, Gerin J L, Purcell RH. Hepatitis delta virus disease. Prog Liver Dis 1986; 8: 417–431
   PubMedGoogle Scholar
• Berk L, de Man RA, Housset C, Berthelot P, Schalm SW. Alpha lymphoblastoid interferon and acyclovir for chronic hepatitis delta. Hepatitis delta virus, JL Gerin. Alan R. Liss, New York 1990, in press
   Google Scholar
• Smedile A, Rizzetto M, Denniston K J, et al. Type D hepatitis: the clinical significance of HDV-RNA in serum as detected by a hybridization-based assay. Hepatology 1986; 6: 1297–1302
   PubMedGoogle Scholar
• Rosina F, Pintus C. Long-term interferon therapy of chronic hepatitis delta virus using recombinant alpha-interferon: A controlled study [Abstract]. Hepatology 1988; 8: 1408
   Google Scholar
• Farci P, Karayiannis P, Brook MG., . Treatment of chronic hepatitis delta virus (HDV) infection with human lymphoblastoid alpha-interferon. Hepatitis delta virus, JL Gerin, et al. Alan R Liss, New York 1990, in press
   Google Scholar
• Hoofnagle JH. Type D (delta) hepatitis. JAMA 1989; 261: 1321–1325
   PubMed Web of Science ®Google Scholar
• Renault P F, Hoofnagle JH. Side-effects of alpha-interferon. Semin Liver Dis, 19: 273–277
   Google Scholar
• Fentiman I S, Thomas B S, Balkwill F R, Rubens R D, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1985; 1: 1166
   PubMedGoogle Scholar